Elevation Oncology Inc (ELEV)
$0.54
Performance
- $0.52$0.56$0.54
3.2%
Downside
Day's Volatility :6.64%
Upside
3.55%
- $0.36$5.83$0.54
32.78%
Downside
52 Weeks Volatility :93.77%
Upside
90.74%
Returns
| Period | Elevation Oncology Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -80.7% | 0.0% |
6 Months | -88.4% | 0.0% |
1 Year | -13.44% | 0.0% |
3 Years | -93.31% | -20.8% |
Highlights
Market Capitalization | 31.8M |
Book Value | $1.48 |
Earnings Per Share (EPS) | -0.68 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.06% |
Return On Equity TTM | -51.87% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -39.7M |
Diluted Eps TTM | -0.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.82 |
EPS Estimate Next Year | -0.88 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1381.48%
Technicals Summary
Sell
Neutral
Buy
Elevation Oncology Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Elevation Oncology Inc | -14.54% | -88.4% | -13.44% | -93.31% | -95.29% |
 Regeneron Pharmaceuticals, Inc. | -12.99% | 6.13% | 19.74% | 81.09% | 249.37% |
 Novo Nordisk A/s | -10.72% | -7.6% | 27.93% | 139.42% | 357.36% |
 Alnylam Pharmaceuticals, Inc. | 5.38% | 70.96% | 58.49% | 30.96% | 253.38% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 154.45% | 168.54% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Elevation Oncology Inc | NA | NA | NA | -0.82 | -0.52 | -0.22 | NA | 1.48 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Elevation Oncology Inc | Buy | $31.8M | -95.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 249.37% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 357.36% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 253.38% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 168.54% | 32.84 | -4.74% |
Insights on Elevation Oncology Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 62.3%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 31.0% return, outperforming this stock by 124.3%
Institutional Holdings
Logos Global Management LP
13.03%Farallon Capital Management, L.L.C.
6.09%TANG CAPITAL MANAGEMENT LLC
5.18%Aisling Capital Management LP
4.80%BlackRock Inc
4.21%Balyasny Asset Management LLC
4.20%
Company Information
elevation oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. we make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. our lead candidate, seribantumab, inhibits tumor growth driven by nrg1 fusions and is currently being clinically tested in the phase 2 crestone study for patients with tumors of any origin that have an nrg1 fusion. learn more about crestone at www.nrg1fusion.com. elevation oncology is backed by aisling capital, vertex ventures hc, qiming venture partners usa, driehaus capital management, and bvf partners.
Organization | Elevation Oncology Inc |
Employees | 29 |
CEO | Mr. Joseph J. Ferra Jr. |
Industry | Miscellaneous |
Discover More
Ft Skybr Crypt & Dig Econ
$0.54
+0.74%
Cadrenal Therapeutics Inc
$0.54
+0.74%
Yieldmax Snow Option Income Strategy Etf
$0.54
+0.74%
Breakwave Tanker Shipping Etf
$0.54
+0.74%
Ubs Ag Etracs Crude Oil Shares Covered Call Etn
$0.54
+0.74%
Old Market Capital Corp
$0.54
+0.74%
Innovator Equity Managed Floor Etf
$0.54
+0.74%
Tiziana Life Sciences Plc
$0.54
+0.74%
Cnic Ice Us Carbon Neutral Power Futures Index Etf
$0.54
+0.74%